Shares of Illumina (ILMN), a leading genomics company, soared 6.16% in pre-market trading on Friday following the release of its impressive third-quarter results and an optimistic outlook for the full year. The company's performance significantly exceeded analyst expectations, demonstrating strong growth in key areas and improved financial metrics.

Illumina reported Q3 revenue of $1.084 billion, surpassing the analyst consensus estimate of $1.065 billion. The company's adjusted earnings per share (EPS) came in at $1.34, handily beating the expected $1.17. This represents a substantial 17.54% increase from the $1.14 per share reported in the same period last year. Additionally, Illumina's adjusted net income of $206 million outperformed analyst projections of $182.2 million.

The robust quarterly performance was primarily driven by growth in the clinical market, Illumina's largest segment, as highlighted by CEO Jacob Thaysen. The company also reported a return to growth outside of China, indicating successful execution of its strategic initiatives aimed at achieving long-term targets. Looking ahead, Illumina raised its fiscal year 2025 guidance, further fueling investor optimism. The company now expects non-GAAP EPS in the range of $4.65 to $4.75, up from its previous estimate of $4.45 to $4.55. This positive outlook, coupled with several analysts raising their price targets, has contributed to the stock's pre-market surge, reflecting growing confidence in Illumina's ability to navigate challenges and capitalize on growth opportunities in the genomics sector.